
According to Benzinga Pro, during Q4, Angion Biomedica (NASDAQ:ANGN) earned $14.89 million, a 194.82% increase from the preceding quarter. Angion Biomedica also posted a total of $25.94 million in sales, a 1676.78% increase since Q3. Angion Biomedica collected $1.46 million in revenue during Q3, but reported earnings showed a $15.70 million loss.